Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 13/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763733 | 0.80 | CHRM3 (0.41) | CHRM3CCR1CHRM2CHRM1CYP2D6 | |
| SCHEMBL5240243 | 0.69 | CCR1 (0.45) | CHRM3CCR1CHRM2CHRM1CYP2D6 | |
| SCHEMBL13116345 | 0.68 | KEAP1 (0.53) | CHRM3CCR1CHRM2CHRM1KCNH2 | |
| SCHEMBL4618235 | 0.68 | KEAP1 (0.53) | CHRM3CCR1CHRM2CHRM1KCNH2 | |
| SCHEMBL4525774 | 0.67 | CYP2B6 (0.47) | CHRM3CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL5240516 | 0.67 | CCR1 (0.43) | CHRM3CCR1CHRM2CHRM1CYP2D6 | |
| SCHEMBL4901870 | 0.67 | CYP2B6 (0.45) | CHRM3CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL6266546 | 0.66 | CYP2B6 (0.56) | CHRM3CYP2B6MAPT | |
| SCHEMBL4006317 | 0.65 | KEAP1 (0.46) | CHRM3CCR1CHRM2CHRM1CHRM4 | |
| SCHEMBL27730036 | 0.65 | CCR1 (0.50) | CHRM3CCR1CHRM2CHRM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | claimed |
| WO-2023141721-A1 | ANTICHOLINERGIC COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | UNIVERSITY OF MONTRÉAL (CA) | 2023-08-03 | — | — | WO | disclosed |
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20100168197-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-07-01 | — | — | US | disclosed |
| US-20100144801-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | disclosed |
| EP-2129663-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2009-12-09 | — | — | EP | disclosed |
| US-20090176856-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-07-09 | — | — | US | disclosed |
| EP-2076261-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2009-07-08 | — | — | EP | disclosed |
| WO-2007007281-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006054162-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006035280-A1 | 3,4-DIHYDROISOQUINOLINE COMPOUNDS AS MUSCRINIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY, URINARY AND GASTROINTESTINAL DISEASES | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006035282-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006016245-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006005980-A1 | XANTHINE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-01-19 | — | — | WO | disclosed |
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2005009340-A2 | METHOD FOR THE TREATMENT OR PREVENTION OF RESPIRATORY DISORDERS WITH A CYCLOOXYGENASE-2 INHIBITOR IN COMBINATION WITH A MUSCARINIC RECEPTOR ANTAGONIST AND COMPOSITIONS THEREWITH | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144801-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885CCR1 574/4885CHRM2 2/4885 |
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CCR1 778/4885CHRM2 2/4885 |
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | CHRM3, CYSLTR2, CHRM2 | CHRM3 1/4885CCR1 993/4885CHRM2 3/4885 |
| US-20100168197-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CCR1 488/4885CHRM2 3/4885 |
| US-20090176856-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CCR1 488/4885CHRM2 3/4885 |
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CCR1 423/4885CHRM2 3/4885 |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CCR1 444/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.